{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:59:07Z","timestamp":1778673547135,"version":"3.51.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-025-24666-0","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T09:58:59Z","timestamp":1761299939000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Gas station heroin- tianeptine and its impact: a systematic review and exploratory analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Shanli","family":"Parnia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshit","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsan","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zouina","family":"Sarfraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Jamal","family":"Nasir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darshini","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiman","family":"FNU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor","family":"Atiq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preet Roshan","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rizwan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hower","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surya","family":"Karlapati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Talha","family":"Moazzam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Bazin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeed","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"24666_CR1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/02791072.2018.1438687","volume":"50","author":"J Springer","year":"2018","unstructured":"Springer J, Cuba\u0142a WJ. Tianeptine abuse and dependence in psychiatric patients: a review of 18 case reports in the literature. J Psychoactive Drugs. 2018;50:275\u201380.","journal-title":"J Psychoactive Drugs"},{"key":"24666_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2174\/157488906775245327","volume":"1","author":"C Brink","year":"2006","unstructured":"Brink C, Harvey B, Brand L. Tianeptine: a novel atypical antidepressant that may provide new insights into the biomolecular basis of depression. RPCN. 2006;1:29\u201341.","journal-title":"RPCN"},{"key":"24666_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.toxrep.2023.07.006","volume":"11","author":"H Galust","year":"2023","unstructured":"Galust H, Seltzer JA, Hardin JR, Friedman NA, Minns A. Tianeptine abuse via novel, extended-release, star-shaped, drug delivery device. Toxicol Rep. 2023;11:162\u20134.","journal-title":"Toxicol Rep"},{"key":"24666_CR4","unstructured":"HAS - Medical, Economic and Public Health Assessment Division. STABLON 12.5\u00a0mg, coated tablet. HAS Sante. 2012. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2013-08\/stablon_ct_10411_12029.pdf. Accessed 18 Feb 2025."},{"key":"24666_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2014.30","volume":"4","author":"MM Gassaway","year":"2014","unstructured":"Gassaway MM, Rives M-L, Kruegel AC, Javitch JA, Sames D. The atypical antidepressant and neurorestorative agent tianeptine is a \u00b5-opioid receptor agonist. Transl Psychiatry. 2014;4:e411\u2013411.","journal-title":"Transl Psychiatry"},{"key":"24666_CR6","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s40122-023-00539-5","volume":"12","author":"AN Edinoff","year":"2023","unstructured":"Edinoff AN, Sall S, Beckman SP, Koepnick AD, Gold LC, Jackson ED, et al. Tianeptine, an antidepressant with opioid agonist effects: pharmacology and abuse potential, a narrative review. Pain Ther. 2023;12:1121\u201334.","journal-title":"Pain Ther"},{"key":"24666_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/00023210-200822010-00002","volume":"22","author":"S Kasper","year":"2008","unstructured":"Kasper S, McEwen BS. Neurobiological and clinical effects of the antidepressant tianeptine. CNS Drugs. 2008;22:15\u201326.","journal-title":"CNS Drugs"},{"key":"24666_CR8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2165\/00023210-200115030-00006","volume":"15","author":"AJ Wagstaff","year":"2001","unstructured":"Wagstaff AJ, Ormrod D, Spencer CM. Tianeptine. A review of its use in depressive disorders. CNS Drugs. 2001;15:231\u201359.","journal-title":"CNS Drugs"},{"key":"24666_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.neuropharm.2017.10.016","volume":"134","author":"P Armenian","year":"2018","unstructured":"Armenian P, Vo KT, Barr-Walker J, Lynch KL. Fentanyl, Fentanyl analogs and novel synthetic opioids: a comprehensive review. Neuropharmacology. 2018;134:121\u201332.","journal-title":"Neuropharmacology"},{"key":"24666_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuropharm.2018.03.037","volume":"134","author":"MA Taffe","year":"2018","unstructured":"Taffe MA, Olive MF. Designer drugs \u2013 a continuing chemical (R)evolution. Neuropharmacology. 2018;134:1\u20133.","journal-title":"Neuropharmacology"},{"key":"24666_CR11","unstructured":"Drug Enforcement Administration, Tianeptine. DEA Diversion. 2024. https:\/\/www.deadiversion.usdoj.gov\/drug_chem_info\/tianeptine.pdf. Accessed 18 Feb 2025."},{"key":"24666_CR12","unstructured":"FDA, Tianeptine. FDA. https:\/\/www.fda.gov\/consumers\/health-fraud-scams\/tianeptine. Accessed 18 Feb 2025."},{"key":"24666_CR13","doi-asserted-by":"publisher","first-page":"815","DOI":"10.15585\/mmwr.mm6730a2","volume":"67","author":"T El Zahran","year":"2018","unstructured":"El Zahran T, Schier J, Glidden E, Kieszak S, Law R, Bottei E, et al. Characteristics of Tianeptine exposures reported to the National poison data system \u2014 United states, 2000\u20132017. MMWR Morb Mortal Wkly Rep. 2018;67:815\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"24666_CR14","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3390\/nutraceuticals3030034","volume":"3","author":"JT Seale","year":"2023","unstructured":"Seale JT, Garden EA, French JMT, McDougal OM. Analysis of tianeptine in dietary supplements. Nutraceuticals. 2023;3:481\u20138.","journal-title":"Nutraceuticals"},{"key":"24666_CR15","unstructured":"Chappell B. 8 things to know about the drug known as gas station heroin. 8 things to know about the drug known as gas station heroin. 2024. https:\/\/www.npr.org\/2024\/07\/12\/nx-s1-4865955\/tianeptine-gas-station-heroin-drug. Accessed 18 Feb 2025."},{"key":"24666_CR16","unstructured":"Congress US. H.R.7068 \u2013 STAND Against Emerging Opioids Act. 118th Congress. Congress. 2024. https:\/\/www.congress.gov\/bill\/118th-congress\/house-bill\/7068\/text. Accessed 18 Feb 2025."},{"key":"24666_CR17","doi-asserted-by":"publisher","unstructured":"Lapsekili N, Yavuz KF. Tianeptine addiction: A case report. J Psychiatry Neurol Sci. 2014;27:81\u20134. https:\/\/doi.org\/10.5350\/DAJPN2014270112.","DOI":"10.5350\/DAJPN2014270112"},{"key":"24666_CR18","doi-asserted-by":"publisher","DOI":"10.5152\/akd.2013.4856","author":"G Ilhan","year":"2013","unstructured":"Ilhan G, Ergene S, Durakoglugil T, Karamustafa H, Karakisi O, Bozok S. Bilateral pseudoaneurysm secondary to intraarterial Tianeptine abuse. Anadolu Kardiyol Derg. 2013. https:\/\/doi.org\/10.5152\/akd.2013.4856.","journal-title":"Anadolu Kardiyol Derg"},{"key":"24666_CR19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/15563650.2020.1781151","volume":"59","author":"W Rushton","year":"2021","unstructured":"Rushton W, Whitworth B, Brown J, Kurz M, Rivera J. Characteristics of Tianeptine effects reported to a poison control center: a growing threat to public health. Clin Toxicol. 2021;59:152\u20137.","journal-title":"Clin Toxicol"},{"key":"24666_CR20","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.forsciint.2007.03.035","volume":"170","author":"P Proen\u00e7a","year":"2007","unstructured":"Proen\u00e7a P, Teixeira H, Pinheiro J, Monsanto PV, Vieira DN. Fatal intoxication with Tianeptine (Stablon\u00ae). Forensic Sci Int. 2007;170:200\u20133.","journal-title":"Forensic Sci Int"},{"key":"24666_CR21","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.psym.2018.07.006","volume":"59","author":"R Lauhan","year":"2018","unstructured":"Lauhan R, Hsu A, Alam A, Beizai K. Tianeptine abuse and dependence: case report and literature review. Psychosomatics. 2018;59:547\u201353.","journal-title":"Psychosomatics"},{"key":"24666_CR22","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/jat\/bky023","volume":"42","author":"EL Bakota","year":"2018","unstructured":"Bakota EL, Samms WC, Gray TR, Oleske DA, Hines MO. Case reports of fatalities involving Tianeptine in the united States. J Anal Toxicol. 2018;42:503\u20139.","journal-title":"J Anal Toxicol"},{"key":"24666_CR23","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0960327110372403","volume":"29","author":"M Ari","year":"2010","unstructured":"Ari M, Oktar S, Duru M. Amitriptyline and tianeptine poisoning treated by naloxone. Hum Exp Toxicol. 2010;29:793\u20135.","journal-title":"Hum Exp Toxicol"},{"key":"24666_CR24","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-1414","volume":"137","author":"C Bence","year":"2016","unstructured":"Bence C, Bonord A, Rebillard C, Vaast P, Alexandre C, Jardri R, et al. Neonatal abstinence syndrome following tianeptine dependence during pregnancy. Pediatrics. 2016;137:e20151414.","journal-title":"Pediatrics"},{"key":"24666_CR25","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/jat\/bkx034","volume":"41","author":"SK Dempsey","year":"2017","unstructured":"Dempsey SK, Poklis JL, Sweat K, Cumpston K, Wolf CE. Acute toxicity from intravenous use of the tricyclic antidepressant Tianeptine. J Anal Toxicol. 2017;41:547\u201350.","journal-title":"J Anal Toxicol"},{"key":"24666_CR26","doi-asserted-by":"publisher","first-page":"769","DOI":"10.15585\/mmwr.mm6727a5","volume":"67","author":"R Goodnough","year":"2018","unstructured":"Goodnough R, Li K, Fouladkou F, Lynch KL, Shah M, Smollin CG, et al. Notes from the Field: toxic leukoencephalopathy associated with Tianeptine Misuse \u2014 California, 2017. MMWR Morb Mortal Wkly Rep. 2018;67:769\u201370.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"24666_CR27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/ADM.0000000000000342","volume":"11","author":"S Gupta","year":"2017","unstructured":"Gupta S, Wallace R, Sloshower J. Online sales of unscheduled pharmaceutical agents: a case report of Tianeptine use in the United States. J Addict Med. 2017;11:411\u20132.","journal-title":"J Addict Med"},{"key":"24666_CR28","doi-asserted-by":"publisher","first-page":"e2023062382","DOI":"10.1542\/peds.2023-062382","volume":"153","author":"K Ikeri","year":"2024","unstructured":"Ikeri K, Anderson A, Eyal F, Whitehurst R. Neonatal opioid withdrawal syndrome following prenatal use of supplements containing Tianeptine. Pediatrics. 2024;153:e2023062382.","journal-title":"Pediatrics"},{"key":"24666_CR29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/PRA.0000000000000448","volume":"26","author":"A Karim","year":"2020","unstructured":"Karim A, Ioannou C. Tianeptine abuse leading to an episode of psychosis: a case report and literature review. J Psychiatr Pract. 2020;26:146\u20138.","journal-title":"J Psychiatr Pract"},{"key":"24666_CR30","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.pnpbp.2007.01.002","volume":"31","author":"C Kisa","year":"2007","unstructured":"Kisa C, Bulbul DO, Aydemir C, Goka E. Is it possible to be dependent to tianeptine, an antidepressant? A case report. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:776\u20138.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"24666_CR31","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.17l02205","author":"S Lucaj","year":"2018","unstructured":"Lucaj S, Leo RJ. Tianeptine sodium: a nootropic with potentially lethal consequences. Prim Care Companion CNS Disord. 2018. https:\/\/doi.org\/10.4088\/PCC.17l02205.","journal-title":"Prim Care Companion CNS Disord"},{"key":"24666_CR32","doi-asserted-by":"publisher","first-page":"356","DOI":"10.9740\/mhc.2022.12.356","volume":"12","author":"M Markovic","year":"2022","unstructured":"Markovic M, Niwash D. Treatment of concurrent etizolam and tianeptine withdrawal following accidental overdose. Ment Health Clin. 2022;12:356\u20139.","journal-title":"Ment Health Clin"},{"key":"24666_CR33","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1080\/15563650.2018.1476694","volume":"56","author":"JM Marraffa","year":"2018","unstructured":"Marraffa JM, Stork CM, Hoffman RS, Su MK. Poison control center experience with tianeptine: an unregulated pharmaceutical product with potential for abuse. Clin Toxicol. 2018;56:1155\u20138.","journal-title":"Clin Toxicol"},{"key":"24666_CR34","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/j.1556-4029.2008.00754.x","volume":"53","author":"A P\u00e9lissier\u2010Alicot","year":"2008","unstructured":"P\u00e9lissier\u2010Alicot A, Gavaudan G, Bartoli C, Kintz P, Piercecchi\u2010Marti M, Desfeux J, et al. Planned complex suicide: an unusual case. J Forensic Sci. 2008;53:968\u201370.","journal-title":"J Forensic Sci"},{"key":"24666_CR35","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/10550887.2023.2290139","volume":"43","author":"VY Rawal","year":"2025","unstructured":"Rawal VY, Gallardo M, Henderson K, Hall OT, Klisovic N, Sikic-Klisovic E. Severe tianeptine withdrawal symptoms managed with medications for opioid use disorder: a case report. J Addict Dis. 2025;43:98\u2013103.","journal-title":"J Addict Dis"},{"key":"24666_CR36","unstructured":"SAAT\u00c7\u0130O\u011eLU \u00d6, ER\u0130M R. \u00c7AKMAK D. A case of Tianeptine abuse. Turkish J Psychiatry. 2006;17:1\u20134."},{"key":"24666_CR37","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1097\/ADM.0000000000001003","volume":"16","author":"L Szczesniak","year":"2022","unstructured":"Szczesniak L, Sullivan R. Microdose induction of buprenorphine in a patient using tianeptine. J Addict Med. 2022;16:736\u20138.","journal-title":"J Addict Med"},{"key":"24666_CR38","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/ADM.0000000000000490","volume":"13","author":"P Trowbridge","year":"2019","unstructured":"Trowbridge P, Walley AY. Use of Buprenorphine-Naloxone in the treatment of Tianeptine use disorder. J Addict Med. 2019;13:331\u20133.","journal-title":"J Addict Med"},{"key":"24666_CR39","first-page":"130","volume":"44","author":"LECHOWICZ W","year":"2000","unstructured":"LECHOWICZ W. Complex intoxication by Tramadol and tianeptine: A case report. J Forensic Sci Issues. 2000;44:130\u20139.","journal-title":"J Forensic Sci Issues"},{"key":"24666_CR40","doi-asserted-by":"publisher","DOI":"10.5152\/TJAR.2013.25","author":"A Sen","year":"2013","unstructured":"Sen A, Ilhan G, Tomak Y, Erdivanli B, Ersoz T, Ergene MS. Role of cultural interaction in Tianeptine abuse and different application methods. Turk J Anesth Reanim. 2013. https:\/\/doi.org\/10.5152\/TJAR.2013.25.","journal-title":"Turk J Anesth Reanim"},{"key":"24666_CR41","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/00952990.2021.1904408","volume":"47","author":"KE Smith","year":"2021","unstructured":"Smith KE, Rogers JM, Strickland JC, Epstein DH. When an obscurity becomes trend: social-media descriptions of Tianeptine use and associated atypical drug use. Am J Drug Alcohol Abuse. 2021;47:455\u201366.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"24666_CR42","doi-asserted-by":"publisher","first-page":"e2444679","DOI":"10.1001\/jamanetworkopen.2024.44679","volume":"7","author":"SM Cohen","year":"2024","unstructured":"Cohen SM, Beetham T, Fiellin DA, Muvvala SB. Availability of medications for opioid use disorder in US psychiatric hospitals. JAMA Netw Open. 2024;7:e2444679.","journal-title":"JAMA Netw Open"},{"key":"24666_CR43","doi-asserted-by":"publisher","first-page":"e2327488","DOI":"10.1001\/jamanetworkopen.2023.27488","volume":"6","author":"CM Jones","year":"2023","unstructured":"Jones CM, Han B, Baldwin GT, Einstein EB, Compton WM. Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021. JAMA Netw Open. 2023;6:e2327488.","journal-title":"JAMA Netw Open"},{"key":"24666_CR44","unstructured":"FDA. Approved Risk Evaluation and Mitigation Strategies (REMS). https:\/\/www.fda.gov\/media\/175628\/download. Accessed 18 Feb 2025."},{"key":"24666_CR45","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2165\/00003495-199549030-00007","volume":"49","author":"MI Wilde","year":"1995","unstructured":"Wilde MI, Benfield P, Tianeptine. A review of its pharmacodynamic and Pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs. 1995;49:411\u201339.","journal-title":"Drugs"},{"key":"24666_CR46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/00004714-200304000-00008","volume":"23","author":"T Nickel","year":"2003","unstructured":"Nickel T, Sonntag A, Schill J, Zobel AW, Ackl N, Brunnauer A, et al. Clinical and neurobiological effects of Tianeptine and Paroxetine in major depression. J Clin Psychopharmacol. 2003;23:155\u201368.","journal-title":"J Clin Psychopharmacol"},{"key":"24666_CR47","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/sj.npp.1300029","volume":"28","author":"H Murck","year":"2003","unstructured":"Murck H, Nickel T, K\u00fcnzel H, Antonijevic IA, Schill J, Zobel A, et al. State markers of depression in sleep EEG: dependency on drug and gender in patients treated with Tianeptine or Paroxetine. Neuropsychopharmacol. 2003;28:348\u201358.","journal-title":"Neuropsychopharmacol"},{"key":"24666_CR48","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.phrs.2018.04.024","volume":"133","author":"S Guerzoni","year":"2018","unstructured":"Guerzoni S, Pellesi L, Pini LA, Caputo F. Drug-drug interactions in the treatment for alcohol use disorders: a comprehensive review. Pharmacol Res. 2018;133:65\u201376.","journal-title":"Pharmacol Res"},{"key":"24666_CR49","first-page":"222","volume":"10","author":"BW Dunlop","year":"2008","unstructured":"Dunlop BW, Davis PG. Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review. Prim Care Companion J Clin Psychiatry. 2008;10:222\u20138.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"24666_CR50","doi-asserted-by":"crossref","unstructured":"Velagapudi V, Calabrese J, Sethi R. Tianeptine as an opiate replacement in a patient on methadone treatment: a case report.\u00a0J Opioid Manag. 2024;20(1):87-91.\u00a0","DOI":"10.5055\/jom.0851"},{"key":"24666_CR51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000118590","volume":"22","author":"JD Guelfi","year":"1989","unstructured":"Guelfi JD, Pichot P, Dreyfus JF. Efficacy of tianeptine in anxious-depressed patients: results of a controlled multicenter trial versus amitriptyline. Neuropsychobiology. 1989;22:41\u20138.","journal-title":"Neuropsychobiology"},{"key":"24666_CR52","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/hup.289","volume":"16","author":"JP Lepine","year":"2001","unstructured":"Lepine JP, Altamura C, Ansseau M, Gutierrez JLA, Bitter I, Lader M, et al. Tianeptine and paroxetine in major depressive disorder, with a special focus on the anxious component in depression: an international, 6-week double\u2010blind study\u2020. Hum Psychopharmacol Clin Exp. 2001;16:219\u201327.","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"24666_CR53","doi-asserted-by":"crossref","unstructured":"Bailey SJ, Almatroudi A, Kouris A. Tianeptine: an atypical antidepressant with multimodal Pharmacology. CPSP. 2018;6:94\u2013110.","DOI":"10.2174\/2211556006666170525154616"},{"key":"24666_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2024.100272","volume":"12","author":"HL Hershey","year":"2024","unstructured":"Hershey HL, Onyango EM, Durst K, Korona-Bailey J, Mukhopadhyay S. Tianeptine-involved emergency department visits, fatal overdoses, and substance seizures in Tennessee, 2021\u20132023. Drug and Alcohol Dependence Reports. 2024;12:100272.","journal-title":"Drug and Alcohol Dependence Reports"},{"key":"24666_CR55","unstructured":"LAPPA. NOVEL PSYCHOACTIVE SUBSTANCES: TIANEPTINE. Legislative Analysis. 2023. https:\/\/legislativeanalysis.org\/wp-content\/uploads\/2023\/03\/Tianeptine-Fact-Sheet-FINAL.pdf. Accessed 18 Feb 2025."},{"key":"24666_CR56","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/bjc\/azq038","volume":"50","author":"CE Hughes","year":"2010","unstructured":"Hughes CE, Stevens A. What can we learn from the Portuguese decriminalization of illicit drugs?? Br J Criminol. 2010;50:999\u20131022.","journal-title":"Br J Criminol"},{"key":"24666_CR57","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.31612","volume":"7","author":"MJ Zoorob","year":"2024","unstructured":"Zoorob MJ, Park JN, Kral AH, Lambdin BH, Del Pozo B. Drug decriminalization, fentanyl, and fatal overdoses in Oregon. JAMA Netw Open. 2024;7:e2431612.","journal-title":"JAMA Netw Open"},{"key":"24666_CR58","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1747-597X-7-25","volume":"7","author":"T Carney","year":"2012","unstructured":"Carney T, Myers B. Effectiveness of early interventions for substance-using adolescents: findings from a systematic review and meta-analysis. Subst Abuse Treat Prev Policy. 2012;7:25.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"24666_CR59","doi-asserted-by":"publisher","first-page":"e225324","DOI":"10.1001\/jamanetworkopen.2022.5324","volume":"5","author":"SE McCabe","year":"2022","unstructured":"McCabe SE, Schulenberg JE, Schepis TS, McCabe VV, Veliz PT. Longitudinal analysis of substance use disorder symptom severity at age 18 years and substance use disorder in adulthood. JAMA Netw Open. 2022;5:e225324.","journal-title":"JAMA Netw Open"},{"key":"24666_CR60","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","volume":"9","author":"K Kampman","year":"2015","unstructured":"Kampman K, Jarvis M. American society of addiction medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9:358\u201367.","journal-title":"J Addict Med"},{"key":"24666_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108868","volume":"226","author":"TL Mark","year":"2021","unstructured":"Mark TL, Hinde JM, Barnosky A, Joshi V, Padwa H, Treiman K. Is implementation of ASAM-based addiction treatment assessments associated with improved 30-day retention and substance use? Drug Alcohol Depend. 2021;226:108868.","journal-title":"Drug Alcohol Depend"},{"key":"24666_CR62","doi-asserted-by":"publisher","first-page":"e241920","DOI":"10.1001\/jamahealthforum.2024.1920","volume":"5","author":"GT Marley","year":"2024","unstructured":"Marley GT, Annis IE, Egan KL, Delamater P, Carpenter DM. Naloxone availability and cost after transition to an over-the-counter product. JAMA Health Forum. 2024;5:e241920.","journal-title":"JAMA Health Forum"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-24666-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-24666-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-24666-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T10:03:45Z","timestamp":1761300225000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-025-24666-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24666"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-24666-0","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"14 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was registered in the PROSPERO database (ID number CRD42024521671). While ethical approval was sought, it was not deemed necessary due to the lack of involvement of human subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3591"}}